Needham & Co reiterates a 'Buy' on Cubist Pharmaceuticals Inc. (Nasdaq: CBST). Price target $27.

Needham analyst says ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE